This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
The company’s main area of focus is cystic fibrosis (CF). The company’s lead marketed products are Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor), Symdeko/Symkevi (tezacaftor in combination with ivacaftor), Orkambi (lumacaftor in combination with ivacaftor) and Kalydeco (ivacaftor), which are collectively approved to treat the majority of the people with CF in North America, Europe and Australia. Trikafta, Vertex’s triple combination regimen, was approved by the FDA in October 2019 for the treatment of CF in people aged 12 years and older who have at least one F508del mutation. Kaftrio (brand name of Trikafta in EU) was approved in the European Union in August 2020. It is also being evaluated in younger patients in the United States. With approval of Trikafta, Vertex can address a significantly larger CF patient population — almost 90% of patients with CF — in the future. Meanwhile, Vertex is pursuing genetic therapies to address the remaining 10% of CF patients. While CF remains the main area of focus, Vertex is also developing treatments for sickle cell disease, thalassemia and pain management.
Top Stock Reports for Apple, JPMorgan & Celgene
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), JPMorgan (JPM) and Celgene (CELG).
The Zacks Analyst Blog Highlights: Crescent Point Energy, Vertex Pharmaceuticals, SodaStream International, Commercial Vehicle Group and Melco Crown Entertainment
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Crescent Point Energy, Vertex Pharmaceuticals, SodaStream International, Commercial Vehicle Group and Melco Crown Entertainment
Can Novartis (NVS) Spring a Surprise This Earnings Season?
by Zacks Equity Research
Swiss pharmaceutical company Novartis AG (NVS) is scheduled to report second-quarter 2017 results on Jul 18.
5 Companies That Consistently Beat Earnings Estimates
by Jeffrey Hymen
Companies that are constantly able to defeat its earnings projections usually exhibit effective management, stronger upward momentum, and more impressive future outlooks.
Amgen's Myeloma Drug Improves Overall Survival in Phase III
by Zacks Equity Research
Biotech major, Amgen, Inc. (AMGN) announced final data from the phase III ASPIRE study, which showed that a combination regimen of its drug, Kyprolis, significantly improved overall survival (OS) in patients with relapsed multiple myeloma.
Biotech Stock Roundup: Arena Shoots Up on Study Data, CELG Inks Immuno-Oncology Deal
by Arpita Dutt
Arena (ARNA) saw it shares shoot up on mid-stage data on its pulmonary arterial hypertension drug while quite a few companies provided regulatory updates.
Zacks.com featured highlights: Sanderson Farms, American Woodmark, Vertex Pharmaceuticals, Baxter International and A. O. Smith
by Zacks Equity Research
Zacks.com featured highlights: Sanderson Farms, American Woodmark, Vertex Pharmaceuticals, Baxter International and A. O. Smith
5 Top Multibagger Biotech Stocks to Buy in the 2nd Half
by Tirthankar Chakraborty
Draconian crackdown on drug prices easing out and likelihood of a series of buyouts will help innovation starved biotech companies to gain in the second half.
Here's Why Investors Are Glued to Vertex Pharma (VRTX) Stock
by Zacks Equity Research
Vertex Pharmaceuticals, Inc. (VRTX), has been attracting investor attention.
Fresh Capital to Be Injected into Biotech Stocks: 5 Must-Buys
by Tirthankar Chakraborty
IBB surged 17% since Trump's win but is still down 23% from its all-time intraday high scaled in the July of 2015.
Biotech Stock Roundup: Clovis Soars on Rubraca Data, Seattle Hit by Study Halt
by Arpita Dutt
Key highlights in the biotech sector include positive data on Clovis' (CLVS) PARP inhibitor, Rubraca.
Zacks.com featured highlights: Etsy, Live Nation Entertainment, Salesforce.com, Vertex Pharmaceuticals and NeoGenomics
by Zacks Equity Research
Zacks.com featured highlights: Etsy, Live Nation Entertainment, Salesforce.com, Vertex Pharmaceuticals and NeoGenomics
5 Toxic Stocks to Discard or Play Short for Profit
by Zacks Equity Research
If you can pinpoint the toxic stocks accurately, you may gain by resorting to an investing strategy called short selling.
Zacks.com featured highlights: Salesforce.com, Vertex Pharmaceuticals, Live Nation Entertainment, Covanta Holding and Etsy
by Zacks Equity Research
Zacks.com featured highlights: Salesforce.com, Vertex Pharmaceuticals, Live Nation Entertainment, Covanta Holding and Etsy
5 Toxic Stocks to Offload or Play Short for Profit
by Zacks Equity Research
Just like identifying stocks with growth potential, spotting toxic stocks and abandoning them at the right time is the key to protect your portfolio from big losses or make profits by short selling them.
Why Is Vertex (VRTX) Up 2.1% Since the Last Earnings Report?
by Zacks Equity Research
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biotech Stock Roundup: FDA Nod for Regeneron RA Drug, Amgen Hit by Study Data
by Arpita Dutt
Key highlights in the biotech sector include FDA approval for Regeneron's (REGN) Kevzara and data from Amgen and Celgene.
Concert Pharma Falls After Clinical Hold on Hair Loss Drug
by Zacks Equity Research
Concert Pharmaceuticals, Inc. (CNCE) shares were down almost 8% on Wednesday after the company announced that the FDA has placed a clinical hold on a mid-stage study evaluating its pipeline candidate CTP-543 for the treatment of alopecia areata.
Vertex Ups Kalydeco Sales View as FDA Okays Label Expansion
by Zacks Equity Research
Vertex Pharmaceuticals Incorporated???s (VRTX) announced that the FDA has approved its lead marketed drug, Kalydeco (ivacaftor) for expanded use.
Zacks.com featured highlights: Covanta Holding, PTC, Etsy, Vertex Pharmaceuticals and Live Nation Entertainment
by Zacks Equity Research
Zacks.com featured highlights: Covanta Holding, PTC, Etsy, Vertex Pharmaceuticals and Live Nation Entertainment
5 Toxic Stocks to Steer Clear Of or Play Short Right Now
by Zacks Equity Research
High price of the toxic stocks can be ascribed to an irrational exuberance associated with them or some serious fundamental lacunae. Presence of such stocks in your portfolio may result loss of wealth.
Biotech Stock Roundup: Biogen Inks Deal to Boost Pipeline, Sangamo Soars on Pfizer Deal
by Arpita Dutt
Quite a few deals were announced this week including by companies like Biogen (BIIB).
Why Is Vertex Pharma (VRTX) Stock Soaring This Year?
by Zacks Equity Research
Vertex Pharmaceuticals, Inc.'s (VRTX) shares have risen 57.8% this year so far, outperforming the increase of 1.3% for the Zacks classified Large-Cap Pharma industry.
Vertex (VRTX) Q1 Earnings Top, CF Products Sales Strong
by Zacks Equity Research
Vertex Pharmaceuticals Incorporated (VRTX) reported first-quarter 2017 earnings per share of 13 cents (including the impact of stock-based compensation expense), which beat the Zacks Consensus Estimate of 4 cents.
What's in Store for Nivalis (NVLS) this Earnings Season?
by Zacks Equity Research
Nivalis Therapeutics, Inc. (NVLS) is expected to report first-quarter 2017 results early next month. Last quarter, the company had a positive surprise of 9.09%.